Clinical Scorecard: Immune Mechanisms in Venous Thrombosis: Coordinating Initiation, Development, and Resolution in a Hypoxic Environment

At a Glance

Key Highlights

• VTE affects up to 5% of the population and has increased incidence during the COVID-19 pandemic. [Needs citation]
• Hypoxia is a critical trigger for venous thrombosis and contributes to a hypercoagulable state. [Needs citation]
• The natural evolution of VT includes initiation, formation, and resolution phases. [Needs citation]
• Thrombus resolution occurs over a period of 21-28 days in murine models and approximately 1 year in humans. [Needs citation]
• Hypoxia-inducible factor (HIF)-1α plays a central role in mediating cellular responses to hypoxia. [Needs citation]

Guideline-Based Recommendations

Diagnosis

• Consider VTE in patients with risk factors, especially in hypoxic conditions. [Needs citation]

Management

• Monitor for signs of VTE in high-risk populations, particularly in ICU settings. [Needs citation]

Monitoring & Follow-up

• Assess for postthrombotic syndrome (PTS) in patients with a history of DVT. [Needs citation]

Risks

• Increased risk of VTE in patients with venous stasis, hypoxia, and endothelial injury. [Needs citation]

Patient & Prescribing Data

Remove unsupported claim about immunomodulatory strategies.

Clinical Best Practices

• Identify and manage risk factors for VTE in hospitalized patients. [Needs citation]
• Utilize thromboprophylaxis in high-risk patients, particularly in ICU settings. [Needs citation]
• Educate patients on the signs and symptoms of VTE and PTS. [Needs citation]

Related Resources & Content

• Venous Thromboembolism Overview
• Hypoxia and Thrombosis